Therapeutic time window of disease‐modifying therapy for early Alzheimer's disease

Abstract Introduction Recently approved disease‐modifying therapies (DMT) for early Alzheimer's disease (AD), including lecanemab and donanemab, require patients to meet specific eligibility criteria for treatment. These criteria define a limited “therapeutic time window,” after which patients becom...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Saki Nakashima, Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Kazushi Suzuki, Atsushi Iwata, Tatsushi Toda, Takeshi Iwatsubo, for Alzheimer's Disease Neuroimaging Initiative
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Wiley 2025-04-01
Serie:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Ämnen:	ADNI Alzheimer's disease disease‐modifying therapy NACC therapeutic window
Länkar:	https://doi.org/10.1002/trc2.70102
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!